Company Profile For Human Genome Sciences, Inc.

Human Genome Sciences (HGS)is a commercially focused biopharmaceutical company. The Company has three products in late-stage clinical development: Albuferon for chronic hepatitis C, LymphoStat-B for systemic lupus erythematosus and ABthraxtm for inhalation anthrax. Albuferon and LymphoStat-B are progressing toward commercialization. In December 2008, the Company reported that Albuferon met its primary endpoint in the first of two Phase III clinical trials in chronic hepatitis C. HGS also has several drugs in earlier stages of clinical development for the treatment of cancer, led by its TRAIL receptor antibody HGS-ETR1 and a small-molecule antagonist of IAP (inhibitor of apoptosis) proteins.

BRIEF: For the nine months ended 30 September 2009, Human Genome Sciences Inc.'s revenues totaled $222.8M, up from $35.5M. Net income totaled $15.4M vs. a loss of $207M. Revenues reflect increased product sales, a rise in manufacturing & development services sales. Net income reflects a decrease in research & development expenses, lower general & administrative expense and lower interest expense.